APVO - Aptevo Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 539.23M
Enterprise Value 326.08M
Trailing P/E N/A
Forward P/E 1-0.86
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)1.51
Price/Book (mrq)1.00
Enterprise Value/Revenue 31.00
Enterprise Value/EBITDA 6-0.55

Trading Information

Stock Price History

Beta (3Y Monthly) 2.47
52-Week Change 3-81.40%
S&P500 52-Week Change 36.69%
52 Week High 35.8000
52 Week Low 30.6700
50-Day Moving Average 30.8449
200-Day Moving Average 31.0783

Share Statistics

Avg Vol (3 month) 3529.25k
Avg Vol (10 day) 3408.16k
Shares Outstanding 522.41M
Float 31.5M
% Held by Insiders 116.31%
% Held by Institutions 141.88%
Shares Short (Jun 28, 2019) 4236.78k
Short Ratio (Jun 28, 2019) 40.36
Short % of Float (Jun 28, 2019) 40.62%
Short % of Shares Outstanding (Jun 28, 2019) 40.53%
Shares Short (prior month May 31, 2019) 4313.58k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin -199.30%
Operating Margin (ttm)-190.65%

Management Effectiveness

Return on Assets (ttm)-34.25%
Return on Equity (ttm)-96.48%

Income Statement

Revenue (ttm)26.02M
Revenue Per Share (ttm)1.09
Quarterly Revenue Growth (yoy)72.50%
Gross Profit (ttm)-23.53M
EBITDA -47.22M
Net Income Avi to Common (ttm)-51.85M
Diluted EPS (ttm)-2.1710
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)37.01M
Total Cash Per Share (mrq)0.82
Total Debt (mrq)23.41M
Total Debt/Equity (mrq)59.83
Current Ratio (mrq)3.15
Book Value Per Share (mrq)0.87

Cash Flow Statement

Operating Cash Flow (ttm)-48.29M
Levered Free Cash Flow (ttm)-26.03M